83 related articles for article (PubMed ID: 24079865)
1. Failure of anti-EGFR therapy in p16-positive head and neck cancer.
Roesler R; Schwartsmann G
Lancet Oncol; 2013 Oct; 14(11):e436-e437. PubMed ID: 24079865
[No Abstract] [Full Text] [Related]
2. Failure of anti-EGFR therapy in p16-positive head and neck cancer - authors' reply.
Vermorken JB; Bach BA
Lancet Oncol; 2013 Oct; 14(11):e437-e438. PubMed ID: 24079867
[No Abstract] [Full Text] [Related]
3. EGFR-directed treatments in SCCHN.
Vokes EE; Seiwert TY
Lancet Oncol; 2013 Jul; 14(8):672-3. PubMed ID: 23746667
[No Abstract] [Full Text] [Related]
4. Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options.
Licitra L; Locati LD; Bossi P
Ann Oncol; 2008 Sep; 19 Suppl 7():vii200-3. PubMed ID: 18790949
[No Abstract] [Full Text] [Related]
5. Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.
Bhatt VR; Ganti AK
Oral Oncol; 2013 Aug; 49(8):e25. PubMed ID: 23631847
[No Abstract] [Full Text] [Related]
6. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
7. [A combination of radiotherapy and chemotherapy with platidiam and fluorouracil in patients with head and neck cancer].
Shparyk IaV; Kravets AI; Bilyns'kyĭ BT; Kuftiak OF
Lik Sprava; 1996; (3-4):153-7. PubMed ID: 9035857
[No Abstract] [Full Text] [Related]
8. EGFR inhibition for recurrent or metastatic HNSCC.
Argiris A
Lancet Oncol; 2015 May; 16(5):488-9. PubMed ID: 25892143
[No Abstract] [Full Text] [Related]
9. Head and neck cancer: second-line afatinib shows promise.
Killock D
Nat Rev Clin Oncol; 2015 Jul; 12(7):373. PubMed ID: 25940985
[No Abstract] [Full Text] [Related]
10. Hyperthermia as an adjuvant to radiation- and/or chemotherapy in far advanced recurrences of the head and neck region.
Steindorfer P; Jakse R; Germann R; Schneider G; Berger A; Mischinger HJ; Rehak P
Strahlenther Onkol; 1987 Jul; 163(7):449-52. PubMed ID: 2441480
[No Abstract] [Full Text] [Related]
11. Chemo re-irradiation in recurrent head and neck cancer: a single institution experience.
Katodritis N; Charalampous H; Vomvas D
J BUON; 2012; 17(2):397. PubMed ID: 22740226
[No Abstract] [Full Text] [Related]
12. [Combination of 5-fluorouracil and high doses of folinic acid in the treatment of recurrent and persistent spinocellular carcinoma of the head and neck. A phase II study].
Bacigalupo A; Benasso M; Cavallari M; Merlano M; Sampietro M; Scasso F; Pallestrini E; Barbieri A; Cantoni E; Grimaldi A
Acta Otorhinolaryngol Ital; 1988; 8(6):575-80. PubMed ID: 3266818
[No Abstract] [Full Text] [Related]
13. [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].
Dufresne A; Gainet M; Stein U; Guardiola E; Pivot X
Bull Cancer; 2003 Jan; 90(1):39-45. PubMed ID: 12609803
[TBL] [Abstract][Full Text] [Related]
14. The expanding role of systemic therapy in head and neck cancer.
Cohen EE; Lingen MW; Vokes EE
J Clin Oncol; 2004 May; 22(9):1743-52. PubMed ID: 15117998
[TBL] [Abstract][Full Text] [Related]
15. [Indications for cytostatic therapy of recurrent cancer].
Schröder M; Stennert E; von Heyden HW; Scherpe A
HNO; 1984 Jun; 32(6):245-8. PubMed ID: 6206035
[TBL] [Abstract][Full Text] [Related]
16. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Patil V; Noronha V; Krishna V; Joshi A; Prabhash K
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):388. PubMed ID: 23434353
[No Abstract] [Full Text] [Related]
17. A phase I-II trial of cisplatin and dichloromethotrexate in squamous cell cancer of the head and neck.
Wheeler RH; Natale RB; Roshon SG; Baker SR
J Clin Oncol; 1984 Jul; 2(7):831-5. PubMed ID: 6539813
[TBL] [Abstract][Full Text] [Related]
18. The SPECTRUM of findings in treatment options for recurrent/metastatic head and neck cancer.
Misiukiewicz K; Posner M
J Comp Eff Res; 2013 Nov; 2(6):533-5. PubMed ID: 24236791
[TBL] [Abstract][Full Text] [Related]
19. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck.
Sandler S; Bonomi P; Taylor B; Showel J; Slayton R; Lerner H
Cancer Treat Rep; 1984 Sep; 68(9):1163-5. PubMed ID: 6541095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
